DNA methylation

New GBM Study PRESERVE Receives $250,000 Grant from NICO Corporation

Retrieved on: 
星期三, 三月 15, 2023
Research, DNA, APS, Medicine, Oncology, MD, Brain, Glioblastoma, Cleveland, IIS, Trial of the century, Neoplasm, Automation, NICO, Patient, Physician, Biology, Drug development, MBA, Myriad, DNA methylation, World Health Organization, Diagnosis, Cleveland Clinic, DSM-IV codes, Collection, GBM, Medical imaging

BOSTON, March 15, 2023 /PRNewswire/ -- NICO Corporation has awarded a $250,000 Investigator Initiated Study (IIS) grant to Manmeet Ahluwalia, MD, MBA, FASCO, deputy director, chief scientific officer and chief of solid tumor medical oncology at Miami Cancer Institute, to improve the understanding of glioblastoma (GBM) heterogeneity through immediate intraoperative biological preservation of brain tissue using the NICO Myriad® and Automated Preservation System® (APS). NICO is participating in the 4th Annual Glioblastoma Drug Development Summit in Boston beginning today where they will showcase its Myriad and APS technologies.

Key Points: 
  • GBM study uses immediate biologically preserved tissue to better understand regional differences in tumor heterogeneity.
  • PRESERVE GBM is a two-year, multi-center study with the primary objective of assessing important scientific differences in the heterogeneity of GBM tumors from 120 patients.
  • The NICO IIS grant program is dedicated to supporting novel pre-clinical and clinical research efforts related to improved patient and economic outcomes using NICO technologies.
  • Learn more about the IIS program, clinical study areas of interest and how to apply for a grant .

Cardio Diagnostics Holdings Inc Launches Revolutionary Blood Test for Early Detection of Coronary Heart Disease

Retrieved on: 
星期二, 二月 28, 2023
Medical Devices, Health, Technology, Artificial Intelligence, Cardiology, Biotechnology, Death, Diabetes, American College, DNA methylation, CHD, DNA, MD, American Heart Association, Hypercholesterolemia, Cardiovascular disease, Risk, Biomarker, Cardio, CVD, Patient, Genetics, Integration, Moyamoya disease, Splenic infarction, Booth, Artificial intelligence, Hypertension, Smoking, Woman, Pharmaceutical industry, Medical device

Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced the launch of PrecisionCHD™, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.

Key Points: 
  • Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced the launch of PrecisionCHD™, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.
  • The company’s initial product, Epi+Gen CHD™, a three-year coronary heart disease risk assessment test, also leveraged the Engine and was launched in 2021.
  • The two tests address the most common form of cardiovascular disease – coronary heart disease – across the entire spectrum, from assessing risk for prevention to early detection.
  • Cardio Diagnostics’ new patent-pending test, PrecisionCHD, aids in the early detection of coronary heart disease to better enable the management of this condition to prevent a symptomatic event such as a heart attack.

Cardio Diagnostics Holdings Inc to Debut PrecisionCHD™ at the American College of Cardiology’s 72nd Annual Scientific Session

Retrieved on: 
星期三, 二月 22, 2023
Technology, Medical Devices, Genetics, Health Technology, Cardiology, Biotechnology, Health, General Health, Artificial Intelligence, Radiation, American College, DNA methylation, ACC, CHD, DNA, MD, Artificial intelligence, Cardiovascular disease, Risk, Biomarker, Cardio, Entrepreneurship, Patient, Cause of action, Moyamoya disease, Pharmaceutical industry

Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced that its newest coronary heart disease test, PrecisionCHD™, will be presented at the American College of Cardiology’s 72nd Annual Scientific Session (ACC.23), taking place in New Orleans, LA, from March 4-6, 2023.

Key Points: 
  • Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced that its newest coronary heart disease test, PrecisionCHD™, will be presented at the American College of Cardiology’s 72nd Annual Scientific Session (ACC.23), taking place in New Orleans, LA, from March 4-6, 2023.
  • “This is an important step in our fight to reduce the global and national heart disease burden.
  • Our presence at ACC this year underscores our continued progress in advancing the current paradigms to better detect and treat cardiovascular disease,” said Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics.
  • Robert Philibert, MD Ph.D., Cardio Diagnostics’ Chief Medical Officer and Co-Founder, said, “the amount of time it takes for my patients to get tested for CHD is longer than I’d like - in some cases, weeks or months.

DNA Methylation Market Report 2022: Increasing Adoption of DNA Methylation Technology in Oncology Research Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
星期一, 一月 23, 2023
Other Health, Research, Pharmaceutical, Oncology, Medical Devices, Genetics, Clinical Trials, Science, Medical Supplies, FDA, Other Science, Health, DNA, Biomarker, Biotechnology, Gene therapy, Fred Hutchinson Cancer Research Center, NGS, PCR, DNA methylation, Patient, Conditional sentence, ACS, Alzheimer's disease, USD, American Cancer Society, Cancer, Esophageal cancer, Gene, Growth, PubMed, Prevalence, Death, Medical device, Fine chemical

The global DNA methylation market size is expected to reach USD 4.22 billion by 2030.

Key Points: 
  • The global DNA methylation market size is expected to reach USD 4.22 billion by 2030.
  • The market is expected to register a CAGR of 14.67% from 2022 to 2030, due to the increased usage of DNA methylation in sequencing analysis.
  • The increased adoption of DNA methylation in the agrigenomics field remains a promising driver of this growth.
  • The growing number of product launches, FDA approvals, and the presence of key market players remains a promising driver of growth in this region
    Chapter 1 DNA Methylation Market: Methodology And Scope
    Chapter 2 DNA Methylation Market: Executive Summary
    Chapter 3 DNA Methylation Market: Industry Outlook
    Chapter 4 DNA Methylation Market: Competitive Landscape
    Chapter 5 DNA Methylation Market: Technology Business Analysis

Alercell Announces the Launch of a New Website Dedicated to its New Early Detection Tests

Retrieved on: 
星期三, 一月 25, 2023
LENA, RUO, Survival, Gene, DNA, Sale, FDA, Cancer, Therapy, DNA methylation, Patient, Food, Vaccine, Pharmaceutical industry, Leukemia

BOZEMAN, Mont., Jan. 25, 2023 /PRNewswire/ -- ALERCELL, INC. announced today that it has launched a new website LENA DIAGNOSTICS ©" www.lenadx.com. The new site is dedicated only to proprietary tests focused on early detection of cancer and leukemia.

Key Points: 
  • The new site is dedicated only to proprietary tests focused on early detection of cancer and leukemia.
  • The RUO LENA Q51® is available for early detection of any type of Leukemia and is a gigantic leap forward in Leukemia detection.
  • The company also preannounced that it intends to launch an early detection lung cancer test in March/April 2023 based on DNA methylation.
  • Early detection enhances drastically the survival rates of patients and Alercell is focusing on making sure that we give every patient the best chances of survival."

Rejuve.AI and TruDiagnostic Collaborate to Create more Accurate Chronological Age Prediction Tools

Retrieved on: 
星期二, 一月 24, 2023
Machine learning, Methylation, Proteomics, Metabolomics, Beta, DNA, Peptide, Partnership, Algorithm, Duke University, Ageing, Protein, Android, DNA methylation, Longevity, Disease, Biology, Research, IOS, Dietary supplement, Medical device

Will concentrate on developing the most accurate chronological age prediction tools available to date.

Key Points: 
  • Will concentrate on developing the most accurate chronological age prediction tools available to date.
  • Will also generate methylation risk scores based on DNA methylation data to predict protein and metabolite concentrations.
  • Machine learning to develop highly accurate chronological age prediction algorithms based on DNA methylation samples.
  • Furthermore, TruDiagnostic and Rejuve.AI will use machine learning to develop highly accurate chronological age prediction algorithms based on over 3,000 unique longitudinal DNA methylation samples.

PacBio Celebrates Nature Methods Naming Long-Read Sequencing "Method of the Year"

Retrieved on: 
星期五, 一月 13, 2023
Abraxis BioScience, Vertebrate Genomes Project, Genome, DNA methylation, DNA, Nature Methods, Economics, Genomics, Science, Chemistry, Doctor of Philosophy, High fidelity, Book

MENLO PARK, Calif., Jan. 13, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today celebrated long-read sequencing being named Nature Methods' "Method of the Year 2022."

Key Points: 
  • MENLO PARK, Calif., Jan. 13, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today celebrated long-read sequencing being named Nature Methods' "Method of the Year 2022."
  • "PacBio has led a transformation of genomics by making long-read sequencing more accurate and accessible than ever with the introduction of HiFi sequencing," said Christian Henry, President and Chief Executive Officer of PacBio.
  • "Nature Methods recognizes the criticality of highly accurate long-read sequencing to continuing to advance genomic research.
  • Nature Methods cited four wish-list items which further long-read sequencing: lower cost, greater accuracy, time savings, and increased application utility.

Burning Rock Received FDA Breakthrough Device Designation for its OverC™ Multi-Cancer Detection Blood Test

Retrieved on: 
星期二, 一月 3, 2023
Cancer, Ovarian cancer, Ageing, Food, Lung, Area studies, NGS, DNA, ASCO, Risk, Liquid biopsy, Disease, Tissue, Patient, Nucleic acid thermodynamics, US Foods, Machine learning, FDA, Quality of life, DNA methylation, ESMO, Pancreatic cancer, Breakthrough, Survival, Diagnosis, Liver, Medical imaging, Water Drops on Burning Rocks

Under the FDA’s Breakthrough Devices Program, the Breakthrough Device Designation is granted to certain medical devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions such as cancer.

Key Points: 
  • Under the FDA’s Breakthrough Devices Program, the Breakthrough Device Designation is granted to certain medical devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions such as cancer.
  • In May 2022, Burning Rock received CE mark for its OverC™ MCDBT manufactured in both the US and China facilities.
  • Today, the FDA Breakthrough Device Designation granted for OverC™ MCDBT would pave the way for a clearer registration path through confirmative performance validation and utility establishment.
  • Mr. Yusheng Han, founder and CEO of Burning Rock, said, “We are very excited that our cfDNA methylation multi-cancer early detection technology has received FDA Breakthrough Device Designation.

Alercell Is All Set to Launch a Leukemia Diagnostic Test Lena Q51(R)

Retrieved on: 
星期四, 十二月 29, 2022
Lung cancer, Cancer, QMUL, CMO, Biotechnology, Knowledge, DNA, LENA, Nanoparticle, Real-time, Genetic testing, Disease, Patient, Gene expression, Genome, NYSE, Infection, Genetics, Gene, Materials science, DNA methylation, Queen Mary University of London, Scheer, School, Diagnosis, Vaccine, Medical imaging, Leukemia, Engineering, Biopolymer

BOZEMAN, MT, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Alercell is all set to launch LENA Q51(R) in January 2023.

Key Points: 
  • BOZEMAN, MT, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Alercell is all set to launch LENA Q51(R) in January 2023.
  • A leukemia diagnostic test based on sequencing DNA will detect up to 51 Genes mutations in Leukemia patients.
  • The first leukemia diagnostic test, LENA Q51®, based on DNA sequencing and could identify up to 51 gene alterations in leukemia patients.
  • The first methylation-based molecular diagnostic test for lung cancer, LENA S1®, will be made available by Alercell later in the first quarter of 2023.

Agilent Announces Acquisition of Avida Biomed, Developer of High-Performance NGS Target Enrichment Workflows for Cancer Research

Retrieved on: 
星期三, 一月 4, 2023
Biotechnology, Technology, Health, Pharmaceutical, Oncology, Health Technology, Research, Software, Genetics, Science, Clinical Trials, Cancer, Precision medicine, Automation, NGS, DNA, Genomics, Liquid biopsy, Acquisition, NYSE, Prognosis, DNA methylation, Workflow, Diagnosis, Medical imaging, Agilent Technologies

Agilent Technologies Inc. (NYSE: A) today announced the acquisition of Avida Biomed, an early-stage life sciences company that develops high-performance target enrichment workflows with unique capabilities for clinical researchers utilizing next-generation sequencing (NGS) approaches to study cancer.

Key Points: 
  • Agilent Technologies Inc. (NYSE: A) today announced the acquisition of Avida Biomed, an early-stage life sciences company that develops high-performance target enrichment workflows with unique capabilities for clinical researchers utilizing next-generation sequencing (NGS) approaches to study cancer.
  • The acquisition complements Agilent’s market-leading SureSelect portfolio and further augments Agilent’s strategy to expand into the high-growth clinical research and diagnostics markets.
  • The chemistries and assays from Avida Biomed are compatible with Agilent’s automation platforms including Magnis and Bravo, which will facilitate efficient scaling of research experiments and routine sample testing.
  • Avida Biomed’s innovative genomics tools enable simultaneous genomic and DNA methylation profiling from a single sample without compromising sensitivity or specificity.